Jazz Pharmaceuticals (JAZZ) had its price target raised by Piper Sandler from $219.00 to $232.00. They now have an "overweight" rating on the stock.
Jazz Pharmaceuticals to present clinical, preclinical data at AACR 2026 [Yahoo! Finance]
A Look At Jazz Pharmaceuticals (JAZZ) Valuation As New Oncology Data Heads To The 2026 AACR Meeting [Yahoo! Finance]
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 [Yahoo! Finance]
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026